Guselkumab is in clinical development for the treatment of moderately to severely active Crohn’s disease. Crohn's disease is a lifelong condition where parts of the digestive system become inflamed causing painful ulcers and inflammation most commonly in the small intestine and colon. The main symptoms of Crohn’s disease are diarrhoea, stomach aches and cramps, blood in stool, tiredness and weight loss. Symptoms often follow a pattern where individuals with the condition have periods of no symptoms or mild symptoms (remission) followed by periods where their symptoms are particularly troublesome (flare-ups or relapses). Treatments are available but there remains an unmet need for additional therapies that target new pathways that may offer greater efficacy and durable long-term disease control.
Guselkumab for treating moderately to severely active Crohn’s disease
Guselkumab is in clinical development for the treatment of moderately to severely active Crohn’s disease. Crohn's disease is a lifelong condition where parts of the digestive system become inflamed causing painful ulcers and inflammation most commonly in the small intestine and colon.